Ting Xu
Fortuna: 367 M $ al 31/05/2026
Fortuna: 367 M $ al 31/05/2026
Fundador de Alphamab Oncology y Suzhou Alphamab Co. Ltd., Ting Xu es actualmente presidente y director general de Suzhou Alphamab Co. Ltd., Director y Gerente General de Jiangsu Alphamab Biopharmaceuticals Co. Ltd (filial de Suzhou Alphamab Co. Ltd.), Presidente y Director General de Alphamab Oncology y Presidente de Suzhou SmartNuclide Biopharmaceutical Co. Ltd. También forma parte del consejo de Suzhou Bionovogene Biotech Co. Ltd., Shanghai Kangjing Bioscience Co. Ltd. y Suzhou Oncoimmune Co. Ltd. En el pasado, Ting Xu ocupó el puesto de científico principal en Biogen Idec, Inc. (Carolina del Norte). Se licenció en la Universidad de Nanjing y se doctoró y graduó en la Academia China de Ciencias.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ALPHAMAB ONCOLOGY 32,4 % | 19/11/2025 | 315.675.016 ( 32,4 % ) | 367 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ALPHAMAB ONCOLOGY | Director Ejecutivo | 01/10/2018 |
Suzhou Alphamab Co., Ltd.
Suzhou Alphamab Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as biotechnology compnay | Fundador | 01/01/2008 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd Pharmaceuticals: MajorHealth Technology Manufactures and distributes therapeutics for cancer treatment | Director Ejecutivo | 01/01/2015 |
Suzhou SmartNuclide Biopharmaceutical Co., Ltd.
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Develops and manufactures radiopharmaceuticals | Fundador | 01/01/2015 |
Suzhou Bionovogene Biotech Co. Ltd. | Director/Miembro de la Junta | - |
Shanghai Kangjing Bioscience Co. Ltd. | Director/Miembro de la Junta | - |
Suzhou Oncoimmune Co. Ltd. | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01/01/2010 |
Suzhou PANOMIX Biomedical Tech Co., Ltd.
Suzhou PANOMIX Biomedical Tech Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Provides metabolomics testing and analysis services | Presidente | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
Nanjing University
Nanjing University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chinese Academy of Sciences
Chinese Academy of Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Suzhou Alphamab Co., Ltd.
Suzhou Alphamab Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as biotechnology compnay | Commercial Services |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd Pharmaceuticals: MajorHealth Technology Manufactures and distributes therapeutics for cancer treatment | Health Technology |
Alphamab Oncology
Alphamab Oncology BiotechnologyHealth Technology Operates as biopharmaceutical company which engages in development manufacturing and commercialization of therapeutics for cancer treatment | Health Technology |
Suzhou SmartNuclide Biopharmaceutical Co., Ltd.
Suzhou SmartNuclide Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Develops and manufactures radiopharmaceuticals | Health Technology |
Suzhou Bionovogene Biotech Co. Ltd. | |
Shanghai Kangjing Bioscience Co. Ltd. | |
Suzhou Oncoimmune Co. Ltd. | |
Suzhou PANOMIX Biomedical Tech Co., Ltd.
Suzhou PANOMIX Biomedical Tech Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Provides metabolomics testing and analysis services | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.